Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof
US-9561264-B2 · Feb 7, 2017 · US
ABCB5 positive mesenchymal stem cells as immunomodulators
US10017738B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10017738-B2 |
| Application number | US-201313832419-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2013 |
| Priority date | May 31, 2006 |
| Publication date | Jul 10, 2018 |
| Grant date | Jul 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for reconstructing a damaged cornea, comprising, administering to a cornea of a subject having a damaged cornea an isolated preparation of ABCB5 positive dermal mesenchymal stem cells, wherein ABCB5 positive dermal cells comprise at least 95% of the isolated preparation of ABCB5 positive dermal mesenchymal stem cells. 2. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are seeded onto a matrix or scaffold. 3. The method of claim 2 , wherein the matrix is a polymeric mesh or sponge. 4. The method of claim 2 , wherein the matrix is a polymeric hydrogel. 5. The matrix of claim 2 , wherein the matrix is a collagen matrix. 6. The method of claim 1 , wherein ABCB5 positive dermal cells comprise at least 99% of the isolated preparation of ABCB5 positive dermal mesenchymal stem cells. 7. The method of claim 1 , wherein the ABCB5 positive dermal mesenchymal stem cells are autologous to the subject. 8. The method of claim 1 , wherein the ABCB5 positive dermal mesenchymal stem cells are non-autologous to the subject. 9. The method of claim 1 , wherein 1×10 7 -1×10 10 of the ABCB5 positive dermal mesenchymal stem cells are administered to the subject. 10. The method of claim 1 , wherein 1×10 8 -1×10 9 of the ABCB5 positive dermal mesenchymal stem cells are administered to the subject.
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the nervous system · CPC title
for non-specific disorders of the connective tissue · CPC title
for joint disorders, e.g. arthritis, arthrosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10017738B2 cover?
- The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to …
- Who is the assignee on this patent?
- Frank Markus H, Childrens Medical Center
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0625. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).